Compare New Era Energy & Digital Inc. Common Stock (NUAI) vs Nuvation Bio Inc. Class A Common Stock (NUVB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
New Era Energy & Digital Inc. Common Stock vs Nuvation Bio Inc. Class A Common Stock — how do they compare? New Era Energy & Digital Inc. Common Stock trades at $4.93 (market cap $668.01M), while Nuvation Bio Inc. Class A Common Stock trades at $4.95 (market cap $1.71B). The key difference: Nuvation Bio Inc. Class A Common Stock is far larger — about 2.6× New Era Energy & Digital Inc. Common Stock's market cap, and New Era Energy & Digital Inc. Common Stock is trading nearer its 52-week high, Nuvation Bio Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold New Era Energy & Digital Inc. Common Stock for 0 Days and Nuvation Bio Inc. Class A Common Stock for 0 Days on average.
| NUAI | NUVB | |
|---|---|---|
Market Cap | $668.01M | $1.71B |
Volume | 6,756,652 | 5,448,712 |
Sector | Technology | Health |
52-Week High | $8.06 | $9.54 |
52-Week Low | $2.35 | $3.41 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $613.36M | $1.30B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About New Era Energy & Digital Inc. Common Stock
New Era Energy & Digital develops large-scale data centers in energy-rich U.S. markets for AI training and inference workloads. Its Texas Critical Data Centers project in the Permian Basin combines modular deployment with flexible power solutions.
Read more on NUAI →About Nuvation Bio Inc. Class A Common Stock
Nuvation Bio Inc. is a biopharmaceutical company focused on oncology, developing novel cancer treatments including taletrectinib (marketed as IBTROZI), a ROS1 inhibitor, and safusidenib, a brain-penetrant IDH1 inhibitor.
Read more on NUVB →
